Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
In the last 90 days, Nuvation Bio Inc. insiders filed 0 open-market purchases and 1 sale; 244 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
13F holders, Q3 2025
Institutional positions in Nuvation Bio Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 203
- +23 vs. Q2 2025
- Shares held
- 220.5M
- −4.14M (−1.8%) vs. Q2 2025
- Total value
- $817.8M
- +$378.8M (+86.3%) vs. Q2 2025
- New holders
- 40
- 83 more added
- Sold out
- 17
- 48 more reduced
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NUVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 244 | $1.33B |
| Q1 2026 | 233 | $947.4M |
| Q4 2025 | 224 | $1.89B |
| Q3 2025 | 203 | $817.8M |
| Q2 2025 | 182 | $439.1M |
| Q1 2025 | 161 | $364.9M |
| Q4 2024 | 160 | $526.0M |
| Q3 2024 | 154 | $428.6M |
| Q2 2024 | 148 | $447.0M |
| Q1 2024 | 124 | $490.1M |
| Q4 2023 | 116 | $202.7M |
| Q3 2023 | 125 | $183.4M |
| Q2 2023 | 124 | $250.2M |
| Q1 2023 | 129 | $228.2M |
| Q4 2022 | 127 | $267.9M |
| Q3 2022 | 122 | $317.5M |
| Q2 2022 | 120 | $503.2M |
| Q1 2022 | 117 | $837.0M |
| Q4 2021 | 105 | $1.32B |
| Q3 2021 | 98 | $1.50B |
| Q2 2021 | 99 | $1.36B |
| Q1 2021 | 73 | $1.48B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Nuvation Bio Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 24,604,159 | $91.0M | 0.00% | −1,128,831−4.4% | Reduced |
| Decheng Capital LLC | 25,954,439 | $96.0M | 16.75% | 00.0% | Unchanged |
| FMR LLC | 50,570,474 | $187.1M | 0.01% | −468,839−0.9% | Reduced |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −4,622,590−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −905,500−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −781,165−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −619,258−100.0% | Sold out |
| X-Square Capital, LLC | 0 | $0 | 0.00% | −310,000−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −282,464−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −187,603−100.0% | Sold out |
| Stonepine Capital Management, LLC | 0 | $0 | 0.00% | −85,300−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −84,246−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −47,419−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −22,100−100.0% | Sold out |
| Atria Investments LLC | 0 | $0 | 0.00% | −21,602−100.0% | Sold out |
| Assenagon Asset Management S.A. | 0 | $0 | 0.00% | −18,209−100.0% | Sold out |
| Rangeley Capital, LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −4,069−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −122−100.0% | Sold out |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| Clear Street LLC | – | – | – | – | Not filed |